Pristiq Extended-Release NDC 0008-1222

NDC codes

FDA NDC Directory

Product NDC (as listed)0008-1222Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00008-1222Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0008-1222-01	00008122201	90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1222-01)Marketed from May 1, 2008
0008-1222-14	00008122214	14 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1222-14)Marketed from May 1, 2008
0008-1222-30	00008122230	30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1222-30)Marketed from May 1, 2008
0008-1222-50	00008122250	100 BLISTER PACK in 1 CARTON (0008-1222-50) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACKMarketed from May 1, 2008

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pristiq Extended-ReleaseSuffix: Extended-Release
Generic name (nonproprietary): desvenlafaxine succinate
Active ingredients: Desvenlafaxine succinate — 100 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021992
Marketing start: May 1, 2008
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Norepinephrine Uptake Inhibitors (Mechanism)Serotonin Uptake Inhibitors (Mechanism)
Identifiers: Product ID 0008-1222_b9acfefd-10c0-4942-9446-18bb456efb68SPL ID b9acfefd-10c0-4942-9446-18bb456efb68SPL set ID 0f43610c-f290-46ea-d186-4f998ed99fceRxCUI 790267, 790290, 1607617, 1607619, 1874553, 1874559UNII ZB22ENF0XRUPC 0300081210306, 0300081222309, 0300081211303
Pharmacologic class: Serotonin and Norepinephrine Reuptake Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400008122201 followed by a unit qualifier and the quantity

Package 00008-1222-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 28, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . PRISTIQ is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021992

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021992
Product	Strength	Form · route	Labeler	Product NDC
Pristiq Extended-Releasedesvenlafaxine succinate	Desvenlafaxine succinate 25 mg/1	Tablet, Extended releaseOral	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-1210
Pristiq Extended-Releasedesvenlafaxine succinate	Desvenlafaxine succinate 50 mg/1	Tablet, Extended releaseOral	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-1211

Pristiq Extended-Release (desvenlafaxine succinate) NDC 0008-1222